I love to listen to podcasts while I am working out or going for a walk. However, I must admit that some of these podcasts are just a background conversation with nothing meaningful being said. While scrolling through LinkedIn I was therefore pleasantly surprised to see a post from Nathan Teuscher showing that he started the Clinical Pharmacology podcast! Nathan …
With the introduction of ChatGPT I was interested to learn how ChatGPT in pharmacometrics might be applied and how this will impact my code writing tasks, especially for doing pharmacokinetic analysis and creating a starting point for basic R applications. My objective of this post was to see whether ChatGPT could write the R code for a shiny application that …
Shiny applications are commonly used as a data dashboard, to automate a (data science) workflow, or to easily build a minimum viable product. Shiny is a great tool if you are working with R (and now also with Python)! This is how RStudio (Posit) explains it: Shiny is an R package that makes it easy to build interactive web apps …
Pharmacometrics is a rapidly growing field that combines pharmacology, mathematics, and statistics to optimize drug development and dosing. It is the science of quantifying drug effects in patients and developing mathematical models to understand and predict drug behavior in humans. Pharmacometricians use mathematical models to describe the relationship between drug exposure and response, and this can help in making informed …
A range of new shiny applications have been published on this website to visualise pharmacokinetic profiles over time and better understand the use of population models. All applications can be accessed from the Applications menu on this website. All code is updated on GitHub https://github.com/michielve PK profile over time Simulate an oral pharmacokinetic profile based on the dose and model …
This page provides an overview of the abbreviations and terminology commonly used in population PK/PD articles.
The information in the covariance matrix Everyone that has worked for longer than a day with NONMEM has a high probability of encountering error messages mentioning the covariance matrix (nonpositive semidefinite…, R matrix algorithmically singular…, etc.) or people ask and discuss whether or why the covariance step of the model was not successful. However, we barely pay any attention to …
Introduction Unsurprisingly, the absorption of drugs is a complex process. Should you try a first-order input? Zero-order? Both?! Especially when a bias in the model fit of your absorption phase is visible, you should pay some attention on quantifying parallel absorption processes. Multiple absorption processes in one model may be used to describe complex absorption profiles of drugs. Indeed, a …
The development of population PK (and PD) models enable the use of individual Bayesian dose optimization. One could use the included covariates to derive the dose of an individual but one could also determine what an individual’s clearance and/or volume of distribution is by measuring one or multiple plasma concentrations after the first dose. Especially when a narrow therapeutic window …
Acknowledgments The idea for this post was based upon the research by Dr. Lloyd Bridge, presented at the British Pharmacological Society meeting December 2018. and published in October 2020 in JPKPD: Hof, F., Bridge, L.J. Exact solutions and equi-dosing regimen regions for multi-dose pharmacokinetics models with transit compartments. J Pharmacokinet Pharmacodyn (2020). https://doi.org/10.1007/s10928-020-09719-8 Introduction When a PK(/PD) model is developed, it is …
The correct reporting of pharmacokinetic data can provide a tremendous amount of information on the clinical pharmacological characteristics of a drug. Small studies with a limited number of plasma samples can already be informative for others, especially in special populations where information is already limited. However, regardless of the sample size of the study, from extensive phase 1 studies to …
Introduction We are not all the same. We know that there is variability originating from physiological differences in the pharmacokinetic and pharmacodynamic (PK/PD) processes between individuals in a population, also called the inter-individual variability or IIV. We also know that the there can be changes in these processes from one day to another, or between two dose administrations, which is …
